Stablepharma secures Innovate UK grant, bridge funding round to launch
Summary
Stablepharma Ltd awarded a second Innovate UK Grant, in partnership with the University Hospital of Southampton NHS Foundation Trust, as they commence a bridge-funding round in Q4 2023. This joint Innovate UK grant will contribute to the progress of Stablepharmas SPVX02, a fridge-free vaccine for the prevention of Tetanus diphtheria, validating its safety and efficacy through first-in-human clinical trials. This is a great endorsement of the work our R&D team are doing to achieve Stablepharmas vision of making fridge-free vaccines a reality, said \xd6zg\xfcr Tuncer, CEO & Executive Director. Professor Saul Faust OBE, of NHS University Hospital of Southampton, will lead and conduct the delivery of the clinical trials for the SPVX02 (Td) vaccine. Stablepharma Ltd recently announced that it will commence a bridge-funding round in Q4 2023 to progress the launch of SPVX02 (Td), a second fridge-free vaccine SPVX06 (Tetanus mono) and their mRNA research programme.